1. P412: LOW EXPOSURE, EXTENDED DOSING MIMICKING CLINICAL EXPOSURES OF ORAL AZACITIDINE SYNERGIZES WITH VENETOCLAX IN PRECLINICAL AML MODELS. (23rd June 2022) Authors: Jeyaraju, D.; Alapa, M.; Polonskaia, A.; Risueno Perez, A.; Hurren, R.; Wang, X.; Gronda, M.; Ahsan, A.; Wang, C.; Subramanyam, P.; Sriganesh, J.; Anand, A.; Bysani Reddy, M.; Ghosh, K.; Kyriakopoulos, C.; Lailler, N.; Hartl, C.; Lopes de Menezes, D.; Schimmer, A.; Hagner, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 312 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL. (23rd June 2022) Authors: Amatangelo, M.; Cheng, Y.; Pierceall, W.; van de Donk, N. W.; Lonial, S.; Wang, M.; Emerson, J.; Hong, K.; Maciag, P.; Peluso, T.; Gandhi, A.; Thakurta, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 758 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗